MedTrace Logo

Olanzapine Combined With Fosaprepitant, Ondansetron, and Dexamethasone for Preventing Nausea and Vomiting in Patients With Testicular Cancer

NCT05244577 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2023-02-06

No results posted yet for this study

Summary

This study aims to investigate the efficacy and safety of olanzapine combined with fosaprepitant, ondansetron and dexamethasone compared with placebo combined with fosaprepitant, ondansetron and dexamethasone in the prevention of nausea and vomiting in germ-cell tumors receiving 5-day cisplatin chemotherapy

Conditions

  • Olanzapine
  • CINV
  • Testicular Cancer by AJCC V6 and V7 Stage
  • Cisplatin

Interventions

DRUG

Olanzapine Tablets

Olanzapine,Ondansetron,Dexamethasone,Fosaprepitant

DRUG

Placebo

Placebo,Ondansetron,Dexamethasone,Fosaprepitant

Sponsors & Collaborators

  • Shi Yanxia

    lead OTHER

Principal Investigators

  • Yanxia Shi, PHD · Sun Yat-sen University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-18
Primary Completion
2023-12-31
Completion
2024-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05244577 on ClinicalTrials.gov